Back to search

Article

Rare event of NTRK3 rearrangement and amplification in esophageal squamous cell carcinoma

2022-03-23

Abstract excerpt

<h4>Background: </h4> TRK tyrosine kinase inhibitors (larotrectinib or entrectinib) can cause an unknown histological response in NTRK fusion-positive cancer patients,and it has been approved by the US Food and Drug Administration.The neurotrophic tyrosine kinase receptor (NTRK) 3 gene rearrangements is a target of tyrosine kinase inhibitors.We attempted to assess the correlation of NTRK3 gene rearrangement and ge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
db731fa2-0809-54c3-bfcb-a01f8bcad522
DOI
10.21203/rs.3.rs-1387968/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Rare event of NTRK3 rearrangement and amplification in esophageal squamous cell carcinomaDOI 10.21203/rs.3.rs-1387968/v2
Select a neighboring publication to make it the new centre.